Press release | reMYND NV today announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program.
IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
reMYND’s CRO receives governmental grant for a continued innovation of its offering
On its Board Meeting of April 28th 2011, the governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization (CRO) for the ‘Evaluation of candidate behavioral and synaptic markers in tra
reMYND's CRO announces quarterly digital Newsletter
With our quarterly Newsletter, we intend to provide our clients and contacts with some additional thoughts for the preclinical in-vivo testing of their experimental Alzheimer therapies. The one-pager will highlight particular aspects of our Services Offering, provide updates on new models and rea
Review in Nature highlights reMYND's discovery platform
In the November 2010 issue of the high impact journal Nature Reviews Drug Discovery, the News&Analysis column has been entirely devoted to the growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases. The column highlights amongst others reMYND’s technology platform and the recently announced Roche-reMYND collaboration for the development of first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease.
reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
The prestigious Journal of Alzheimer's Disease publishes new data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer’s disease of the APP[V717I] London transgenic mouse model.